F.D.A. Declines to Approve MDMA Therapy, Seeking More Study
Posted inClinical Trials Drug Enforcement Administration Drugs (Pharmaceuticals) Ecstasy (Drug) Food and Drug Administration LSD (Lysergic Acid Diethylamide) Lykos Therapeutics Mental Health and Disorders Post-Traumatic Stress Disorder Psilocybin Mushrooms Psychedelic and Hallucinogenic Drugs Psychology and Psychologists Regulation and Deregulation of Industry Research Therapy and Rehabilitation Veterans

F.D.A. Declines to Approve MDMA Therapy, Seeking More Study

The agency said there was insufficient data to allow the use of a treatment for PTSD that involves the drug known as Ecstasy, according to the company seeking approval.
Veterans and Lawmakers Lobby for Approval of MDMA Therapy
Posted inBergman, Jack (1947- ) Clinical Trials Depression (Mental) Drugs (Pharmaceuticals) Ecstasy (Drug) Food and Drug Administration House of Representatives Institute for Clinical and Economic Review LSD (Lysergic Acid Diethylamide) Lykos Therapeutics Mental Health and Disorders Post-Traumatic Stress Disorder Psilocybin Mushrooms Psychedelic and Hallucinogenic Drugs Psychiatry and Psychiatrists Regulation and Deregulation of Industry Research Therapy and Rehabilitation Veterans

Veterans and Lawmakers Lobby for Approval of MDMA Therapy

The F.D.A. is poised to rule on the therapeutic use of the club drug Ecstasy, a potential watershed moment in the nascent field of psychedelic medicine.
A Blood Test Accurately Diagnosed Alzheimer’s 90% of the Time, Study Finds
Posted inAlzheimer's Disease Blood Brain Clinical Trials Computerized Axial Tomography (CAT Scans) Dementia Doctors JAMA (Journal of American Medical Assn) Memory Research Tests (Medical) your-feed-healthcare your-feed-science

A Blood Test Accurately Diagnosed Alzheimer’s 90% of the Time, Study Finds

It was much more accurate than primary care doctors using cognitive tests and CT scans. The findings could speed the quest for an affordable and accessible way to diagnose patients with memory problems.
Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug
Posted inAcademic and Scientific Journals Alzheimer's Disease Appointments and Executive Changes Cassava Sciences Inc City College of New York Clinical Trials Drugs (Pharmaceuticals) Falsification of Data Research Securities and Commodities Violations your-feed-science

Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug

The chief executive and a lead scientist stepped down weeks after a federal grand jury filed fraud charges against a research collaborator.